Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
1. BVS reported Q4 adjusted EPS of 15 cents, exceeding expectations. 2. Sales reached $153.6 million, up 13.5% year-over-year. 3. Pain treatment and surgical solutions drove significant sales growth. 4. Adjusted EBITDA improved to $28.3 million, up 28.3%. 5. 2025 sales guidance is $560-$570 million, surpassing consensus.